无症状重度主动脉瓣狭窄:早期手术换瓣优于保守观察——AVATAR试验长期随访
AVATAR试验将157例无症状重度主动脉瓣狭窄且左室射血分数≥50%的低危患者随机分为早期外科主动脉瓣置换组与保守观察组,中位随访63个月。
要点
- 无症状重度AS且LVEF≥50%的低危患者,早期外科AVR显著降低主要复合终点事件。
- 中位随访63个月,早期手术组主要复合终点发生率为23.1%,保守组为46.8%。
- 全因死亡(HR 0.44)和心衰住院(HR 0.21)风险在早期手术组均显著更低。
核心结论
- 在真正无症状的重度主动脉瓣狭窄且左室射血分数正常的低危患者中,与保守观察策略相比,早期外科主动脉瓣置换可改善临床结局。
研究设计与样本
- AVATAR试验为随机对照试验,纳入157例低危患者(平均年龄67岁,57%为男性,平均STS评分1.7%),随机分为早期外科AVR组(n=78)和保守治疗组(n=79)。
- 所有患者运动负荷试验均为阴性,主要假设为早期AVR可减少由全因死亡、急性心肌梗死、卒中或非计划心衰住院组成的主要复合终点。
临床怎么用
- 对于真正无症状、LVEF≥50%且运动负荷试验阴性的重度AS低危患者,可考虑早期外科AVR以降低死亡和心衰住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The question of when and how to treat truly asymptomatic patients with severe aortic stenosis (AS) and normal left ventricular (LV) systolic function is still subject to debate and ongoing research. Here, the results of extended follow-up of the AVATAR trial are reported (NCT02436655, ClinicalTrials.gov). METHODS: The AVATAR trial randomly assigned patients with severe, asymptomatic AS and LV ejection fraction ≥ 50% to undergo either early surgical aortic valve replacement (AVR) or conservative treatment with watchful waiting strategy. All patients had negative exercise stress testing. The primary hypothesis was that early AVR will reduce a primary composite endpoint comprising all-cause death, acute myocardial infarction, stroke, or unplanned hospitalization for heart failure (HF), as compared with conservative treatment strategy. RESULTS: A total of 157 low-risk patients (mean age 67 years, 57% men, mean Society of Thoracic Surgeons score 1.7%) were randomly allocated to either the early AVR group (n = 78) or the conservative treatment group (n = 79). In an intention-to-treat analysis, after a median follow-up of 63 months, the primary composite endpoint outcome event occurred in 18/78 patients (23.1%) in the early surgery group and in 37/79 patients (46.8%) in the conservative treatment group [hazard ratio (HR) early surgery vs. conservative treatment 0.42; 95% confidence interval (CI) 0.24-0.73, P = .002]. The Kaplan-Meier estimates for individual endpoints of all-cause death and HF hospitalization were significantly lower in the early surgery compared with the conservative group (HR 0.44; 95% CI 0.23-0.85, P = .012, for all-cause death and HR 0.21; 95% CI 0.06-0.73, P = .007, for HF hospitalizations). CONCLUSIONS: The extended follow-up of the AVATAR trial demonstrates better clinical outcomes with early surgical AVR in truly asymptomatic patients with severe AS and normal LV ejection fraction compared with patients treated with conservative management on watchful waiting.
引用
- Banovic M, Putnik S, Da Costa BR, et al. Aortic valve replacement vs. conservative treatment in asymptomatic severe aortic stenosis: long-term follow-up of the AVATAR trial. Eur Heart J. 2024. PMID: 39217448. doi:10.1093/eurheartj/ehae585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。